SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Therefore, biomarkers to evaluate underlying mechanisms of action of SGLT2 inhibitors on the liver have now been scrutinized to assess their potential as a future in-label therapy for NAFLD.